Mitomycin C for metastatic prostate cancer: Final analysis of a randomized trial

Anticancer Research

Volumn 19, Issue 3 B, 1999, Pages 2157-2161

  Boel, K ^f   Van Poppel, H ^f   Goethuys, H ^f   Derluyn, J ^a   Vandenbroucke, F ^a   Popelier, G ^b   Casselman, J ^c   Billiet, I ^d   Vanuytsel, L ^f   Paridaens, R ^f   Baert, Luc ^e  

^a Sint Jozefskliniek   (Belgium)

^b Division of Urologic Surgery   (Belgium)

^c Division of Urology   (Belgium)

^d Algemeen Ziekenhuis Sint Maarten   (Belgium)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f NONE

Author keywords

Chemotherapy; Metastatic prostate cancer; Mitomycin C; Orchiectomy

Indexed keywords

ANTINEOPLASTIC AGENT; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DYSPNEA; HORMONAL THERAPY; HORMONE RESISTANCE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; NEPHROTOXICITY; ORCHIECTOMY; PHLEBITIS; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTIBIOTICS, ANTINEOPLASTIC; COMBINED MODALITY THERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM METASTASIS; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0032781052     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Isaacs JT, Heston WDW, Weissman RM, Coffey DS:Animal models of hormone-sensitive and hormone-insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT. Cancer Res 38: 4353-4359, 1978.
2. Jones WG: Is there a place for chemotherapy of prostatic cancer? Am J Clin Oncol 11: S98, 1988.
3. Torti FM, Carter SK: The chemotherapy of prostatic adenocarcinoma. Ann Intern Med 92: 681-689, 1980.
4. Jones WG, Fossa SD, Bono AV, Croles JJ, Stoter G,. Depauw M, Sylvester R: Mitomycin C in the treatment of metastatic prostate cancer. Report on an EORTC phase II study. World J Urol 4: 182-185, 1986.
5. Newling DWW, Fossa SD, Tunn UW, Kurth KH, De Pauw M, Sylvester R: Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: The final analysis of the EORTC GU Group prospective randomized Phase III study (30865). J Urol 150: 1840-1844, 1993.
6. Harmer MH: TNM classification of Malignant Tumours, 3rd ed. Geneva: International Union Against Cancer, 1978.
7. Mostofi SK, Sesterhenn I, Sobin LH: International Histological Classification of Tumours. NΓ22, Histological Typing of Prostate Tumours. Geneva: World Health Organization, 1980.
8. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No 48, Geneva: World Health Organization, 1979.
9. Van Poppel H, Vandenbroucke F, Derluyn J, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L: Mitomycine C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial. J Urol 149: 1485-1487, 1993.
10. Vandenbroucke F, Van Poppel H, Derluyn J, Popelier G, Casselman J, Billiet I, Vanuytsel L, Paridaens R, Baert L: Interim results on a randomized trial of Mitomycine C with orchiectomy for newly diagnosed metastatic prostate cancer. Am J Clin Oncol 18: 263-266, 1995.
11. Keuppens FI, Kliment J, Robinson MR, De Reijke TM, Rea LA, Sylvester RJ: Final results of a prospective EORTC multicenter randomized phase III study comparing orchidectomy and orchidectomy + Mitomycin C in patients with poor prognosis metastatic prostate cancer. J Urol suppl. 157 (Suppl. 4): 320, 1997.
12. Fossa SD, Curran D, Aaronson N, Keuppens F, Kliment J, Robinson MRG, De Reijke TM, Hetherington J, Kil PJM, Rea LA: Quality of life of patients with newly diagnosed M1 prostate cancer undergoing orchiectomy without or with Mitomycin C: results from EORTC phase III trial 30893. Eur J Cancer 33 (Suppl. 8): S29, 1997.
13. Pummer K: Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostate cancer. Sem Oncol 18 (Suppl. 6): 26,1991.
14. Pummer K: Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32 (Suppl. 3): 81-85, 1997.
15. Manni A, Santen RJ, Boucher A, Lipton A, Harvey H, Simmonds M, White D, Gordon R., Ronher T, Drago J: Hormone stimulation and chemotherapy in advanced prostate cancer: preliminary results of a prospective controlled clinical trial. Anticancer Res 5: 161-165, 1985.
16. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Cappin CML, Murphy KC: Chemotherapy with mithoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints. J Clin Oncol 14: 1756-1764, 1996.
17. Kuzel TM, Tallman MS, Shevrin D, Braud E, Kilton L, Johnson P, Kozlowski J, Vogelzang NJ, Blough R, Benson AB: A phase II study of continuous infusion 5-fluorouracil in advanced hormone refractory prostate cancer. Cancer 72: 1965-1968, 1993.
18. Hudes G: Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone-refractory prostate cancer. J Clin Oncol 10: 1754-1761, 1992.